openPR Logo
Press release

A Detailed Analysis of the COVID 19 Impact on Antihyperlipidemic Drugs Market

07-31-2020 05:05 PM CET | Health & Medicine

Press release from: Allied Market Research

Antihyperlipidemic Drugs Market

Antihyperlipidemic Drugs Market

According to a new report entitled "Antihyperlipidemic Drugs Market by Drugs: Global Opportunity Analysis and Industry Forecast, 2019-2026," published by Allied Market Research, the global hyperlipidemia treatment market was valued at $9,456 million in 2018, 2019 The average annual growth rate was 7.5% from 2026 to $16,865 million by 2026.

Elevated lipid levels in the blood are called hyperlipidemia. Drugs used to treat this condition are called antihyperlipidemic drugs. There are also major complications associated with this condition, such as a heart attack. Therefore, the condition requires early monitoring and treatment. Some of the commercially available antihyperlipidemic drugs include statins, bile acid sequestrants, cholesterol, and more.

Click here to access the free sample report:

The sedentary lifestyle is a major factor contributing to the growth of the antihyperlipidemic market. In addition, the proliferation of disorders related to the distribution of cholesterol in the blood contributes to the growth of the hyperlipidemic drug market. In addition, a surge in awareness of complications related to hyperlipidemia is another major factor driving market growth. However, high treatment costs are expected to hinder market growth. Conversely, growth opportunities shown by emerging economies are expected to provide profitable opportunities during the forecast period.

know more:

The antihyperlipidemic drug market size is studied by segment, drug type and region to provide a detailed assessment of the market. Depending on the type of drug, the market is divided into statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives and combinations. It is analyzed in North America (USA, Canada and Mexico), Europe (Germany, France, UK, Italy, Spain and other Europe), Asia Pacific (China, Japan, India, Australia) by region. , Korea and other Asia Pacific regions) and LAMEA (Brazil, South Africa and the rest of LAMEA).

According to the drug classification, statins occupied the largest market share of hyperlipidemia treatments in 2018 as the incidence of cardiovascular disease soared. Statins are also another major factor contributing to the growth of the market by reducing the risks associated with heart attacks. In addition, the PCSK9 inhibitor segment is expected to record the fastest growth during the forecast period due to benefits such as a sharp decrease in LDL levels in the blood. Other factors driving market growth include a surge in the elderly population and an increase in healthcare costs worldwide. In addition, other factors driving market growth include additional benefits provided by statins, such as improved endothelial function, improved stability of atherosclerotic plaques, and reduced amounts of inflammation and damage to cells due to oxidative stress.

In 2018, North America occupied a major share of the hyperlipidemic drug market size and is expected to maintain its edge over the forecast period due to the availability of hyperlipidemic drugs. In addition, a surge in sedentary lifestyle is another key factor contributing to the growth of the market. In addition, a surge in the obesity population is another major factor driving growth in the antihyperlipidemic market. In addition, Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc. The presence of major key companies such as, etc. is another key factor driving the growth of the hyperlipidemia treatment market in the region. The Asia Pacific region, on the other hand, is believed to have experienced the fastest growth during the forecast period, with a surge in awareness of antihyperlipidemic use.

Purchase Inquiries:

Developing countries offer a favorable opportunity for antihyperlipidemic agents to expand their business. The ever-evolving life sciences industry drives growth in developing countries such as India and China. In addition, this report includes detailed quantitative analysis to identify dominant opportunities along with strategic assessments along with global hyperlipidemic drug market trends from 2019 to 2026.

The main results of the study:
• Statins accounted for a third of the world's hyperlipidemic drug market in 2018.
• PCSK9 inhibitor segments are expected to grow to the highest CAGR during the forecast period.
• The cholesterol absorption inhibitor segment accounted for more than a quarter of the market share in 2018.
• The Asia Pacific region is expected to grow at the highest rate during the analysis period, followed by LAMEA.

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
Follow Us on LinkedIn:

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release A Detailed Analysis of the COVID 19 Impact on Antihyperlipidemic Drugs Market here

News-ID: 2101163 • Views: 285

More Releases from Allied Market Research

North America Geogrid Market 2020 Segmentation, Demand, Growth, Trend, Opportuni …
According to the report published by Allied Market Research, the North America geogrid market generated $282.0 million in 2019, and is estimated to reach $408.25 million by 2027, registering a CAGR of 7.0% from 2020 to 2027. The report offers an extensive analysis of changing market dynamics, key winning strategies, business performance, major segments, and competitive scenarios. Surge in infrastructure development activities across the U.S. and Mexico and superior physical properties
Intravenous Immunoglobulin (IVIG) Market 2020 In-Depth Analysis of Industry Shar …
Global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds
Asthma and COPD Drugs Market Is Expected to Witness a Steady Growth by 2026
"Asthma and COPD Drugs Market by Disease and Medication Class - Global Opportunity Analysis and Industry Forecasts, 2014-2022", projects that the global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America
Synthetic Biology Market in Global Industry by Top Companies, Type and Applicati …
Global Synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020). Europe occupies largest share in the global market and would hold-on to its position throughout 2020. However, Asia Pacific is the fastest growing market with a CAGR of 46.4% from 2014 - 2020. Read Full Report @ Synthetic biology is at a nascent stage and has recently

All 5 Releases

More Releases for Drugs

Global Cardiovascular Drugs Market
Global Cardiovascular Drugs Market – Industry Analysis and Forecast (2018-2026) – by Drug Class, Indications, Distribution Channels, and Region. Global Cardiovascular Drugs Market was valued at US$ 80.5 Bn in 2017 and is expected to reach US$ 98.8 Bn by 2026, at a CAGR of 2.6 % during the forecast period. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data,
Cardiovascular Drugs Market | Insights
Some of the common cardiovascular diseases include hypertensive heart disease, rheumatic heart disease, ischemic heart disease, inflammatory heart disease, and cerebrovascular heart disease. Major problems associated with hypertensive heart disease include angina, hypertrophy, and heart failure. These problems are caused due to high blood pressure in the heart’s arteries and muscles, which causes narrowing of arteries and thickening and enlargement of heart. The global cardiovascular drug market is primarily driven
Immunotherapy Drugs Market
Immunotherapy drugs are used to treat cancer, infection, respiratory and autoimmune disorders. Immunotherapies either stimulate the activities done by specific components of the immune system or counteract the signals that are produced by the cancer cells and suppress the immune responses. The Immunotherapy Drugs Market accounted to USD 107 billion in 2016 growing at a CAGR of 13.2% during the forecast period of 2017 to 2024. The upcoming market report contains
Immunotherapy Drugs Market
Immunotherapy is the management of a disease by enhancing, suppressing, or inducing an immune response. Some immunotherapies are designed to magnify or elicit an immune response. They are known as activation immunotherapies. However, some immunotherapies that suppress or reduce the immune response are known as suppression immunotherapies. Cell-based immunotherapies are useful for some types of cancers. Immune effector cells includingmacrophages, dendritic cells, lymphocytes, cytotoxic T lymphocytes (CTL), natural killer cells
Tardive Dyskinesia Drugs Market
Tardive dyskinesia (TD) is a form of dyskinesia that is difficult to treat. It is a nerve disorder characterized by involuntary movements such as jaw, lips, and tongue, considered as grimacing, sticking the tongue out, and lip smacking. Some other symptoms are an individual experiencing involuntary movement of the lower and upper extremities and also breathing choking. According to Center for Drug Evaluation and Research, tardive dyskinesia can lead to
Erythropoietin Drugs Market
Erythropoietin alfa is widely used to treat anemia and increase the red blood cells count in the body. Erythropoietin drugs are developed in vitro by extracting the erythropoietin from the human body and developing it through the use of recombinant DNA technology. Erythropoietin drugs are also used to treat anemia induced from cancer, multiple myloma and HIV associated anemia. Recombinant DNA technology has allowed researchers to develop synthetic forms of